Figure 5

Acute exposure of gemcitabine inhibits the further raise of dNTPs in single Vpx + VLP MDMs. To further validate that gemcitabine does not have off target effects, MDMs were first treated with VLPs for 22.5 h before the addition of 40 and 100 nM gemcitabine to the medium. Samples were processed for dNTPs 1.5 h after gemcitabine addition. (A) dATP, (B) dGTP, (C) dCTP, and (D) dTTP concentrations were determined and means for two independent MDM donors plotted. Two-way ANOVA analysis was performed and significant differences denoted on the graphs. Importantly, acute exposure of gemcitabine for 1.5 h caused a much greater inhibition in the further raise of dCTP, dGTP and dATP levels treatment as compared to no gemcitabine control sample, while only having a modest influence on dTTP pool size.